Whole exome sequencing of 4 patient-derived astrocytoma cell lines
IDH1-mutant low-grade astrocytomas are slow-growing tumors arising from glial cells. They exhibit characteristic mutations, including TP53 alterations and ATRX loss, in addition to the IDH1 R132H mutation. Without proper treatment, low-grade astrocytomas have a tendency to progress to higher grades, often due to the acquisition of additional mutations, such as CDKN2A/B loss, SMARCA4 and MYC alterations, or PDGFRA and MET amplification. Today, it remains challenging to study these tumors in vitro, mostly due to the lack of tools. To solve this problem, our team developed a protocol to isolate patient-derived cell lines. We maintained four cell lines for at least 10 passages from four donors: 2 were grade 2 (LGG275 and LGG336), and the other 2 were grade 4 (LGG85 and LGG349). To confirm the reliability and usefulness of this biobank, we conducted a thorough characterization of these cell lines. One of the points was to validate, using whole-exome sequencing (WES), that the 4 cell lines still carried the mutation found in patients.